CRISPR Therapeutics' CTX001 trial in beta-thalassemia underway

|About: CRISPR Therapeutics (CRSP)|By:, SA News Editor

CRISPR Therapeutics (CRSP -2.7%) slips of the gate this morning following its Q3 report released after the close yesterday.

The first patient has been enrolled in a European study evaluating gene therapy CTX001 in patients with an inherited blood disorder called β-thalassemia. Based on acceptable safety data on the first two participants, the trial up enrollment to as many as 45 patients.

Q3 results: Collaboration revenue: $563K; net loss: ($50.7M).

Subscribe for full text news in your inbox